Cutting-Edge PET/CT Scanner Is Clinically Operational

Publication
Article
OncologyONCOLOGY Vol 16 No 6
Volume 16
Issue 6

The world’s first clinically operational molecular imager with lutetium oxyorthosilicate (LSO) technology-the biograph LSO, manufactured by Siemens Medical Solutions-has produced a precisely registered, combined positron-emission tomography (PET)/computed tomography (CT) image in 7 minutes at the Hong Kong Baptist Hospital. The biograph LSO imager uses the high-speed properties of LSO as the PET scintillator to provide shorter scan times and unmatched patient throughput.

The world’s first clinicallyoperational molecular imager with lutetium oxyorthosilicate (LSO) technology—thebiograph LSO, manufactured by Siemens Medical Solutions—has produced aprecisely registered, combined positron-emission tomography (PET)/computedtomography (CT) image in 7 minutes at the Hong Kong Baptist Hospital. Thebiograph LSO imager uses the high-speed properties of LSO as the PETscintillator to provide shorter scan times and unmatched patient throughput.

The biograph LSO merges three components—the ECAT ACCEL PETscanner, the SOMATOM Emotion spiral CT scanner, and syngo multimodality software—intoa powerful scanning device that creates a precisely registered molecular imagein 15 minutes or less. The resulting image makes it possible for oncologists andother health-care providers to view detailed anatomy and the biologicalprocesses of internal organs and living tissue at the molecular level in asingle, noninvasive diagnostic procedure.

In addition to the biograph LSO, the biograph is available with bismuthgermanate (BGO) crystal technology—a proven and economic scintillator forquality high-resolution PET imaging. The first commercial installation of thebiograph with BGO technology was completed last fall at Memorial Sloan-KetteringCancer Center in Manhattan.

Recent Videos
Barriers to access and financial toxicities are challenges that must be addressed for CAR T-cell therapies in LBCL, according to Jose Sandoval Sus, MD.
Fixed treatment durations with bispecific antibodies followed by observation may help in mitigating infection-related AEs, according to Shebli Atrash, MD.
2 experts are featured in this series.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
2 experts are featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Shebli Atrash, MD, stated that MRD should be considered carefully as an end point, given potential recurrence despite MRD negativity.